BRIEF—Bayer expands label for Eylea in China

Germany’ Bayer has successfully expanded the label for its ophthalmic medicine Eylea (aflibercept) in China, to include the treatment of neovascular age-related macular degeneration.

In February, the Chinese medicines regulator gave the green light for the drug’s use against visual impairment through diabetic macular edema. The biologic is now approved in about 100 countries in five indications.